EUVIMEDEUVIMED entdecken
Multizentrische Studie

Impact of Lack of Access to Immunotherapy on Survival in Stage IV Non–Small Cell Lung Cancer: A Multicenter Retrospective Study From Lebanon

Mohammad Hassan Hodroj iD, Hasan Numan iD, Laura El-Halabi, Firas Rammal iD, Ali Ghais iD, Rami Tfayli, Abdallah Bou Orm, Maya Charafeddine iD, Cendrella Bou Orm iD, Karim Haddad, Samah Seif iD, Hady Ghanem iD und 6 weitere

JCO Global Oncology · 2026-07 · 12 (7)

DOI: 10.1200/go-26-00203 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift JCO Global Oncology, 2026-07. Verfasst von Mohammad Hassan Hodroj und 17 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology and Oncology, Naef K. Basile Cancer Institute, American University of Beirut Medical Center, Beirut, Lebanon. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Immunotherapy. Die Arbeit nennt 18 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Lung cancer remains the leading cause of cancer-related mortality worldwide. Immune checkpoint inhibitors (ICIs) have become the standard of care for stage IV non–small cell lung cancer (NSCLC). In 2021, Lebanon experienced a severe economic collapse that resulted in major shortages of immunotherapy and treatment interruptions. The aim of this study was to explore the potential impact of immunotherapy shortage on progression-free survival (PFS). METHODS This retrospective multicenter study included patients with newly diagnosed stage IV NSCLC treated between January 2019 and December 2020 (control group) and between October 2021 and December 2022 (crisis group). The primary end point was PFS, defined from treatment initiation to progression according to RECIST 1.1 criteria or death. Kaplan-Meier survival curves were generated, and differences were assessed using log-rank test. RESULTS A total of 500 medical records were reviewed; 158 eligible patients were included (73 control, 85 crisis). The total cohort included 60.8% men with a mean age of 69.7 years. Among immunotherapy recipients, 44.0% received full-dose therapy (dose density ratio = 1.0), 41.4% received 50%-99% of standard dose (dose density ratio = 0.50-0.99), and 14.7% received

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsImmunotherapyHumansRetrospective StudiesMaleLebanonFemaleAgedNeoplasm StagingMiddle Aged

Autor:innen und Institutionen

  • Division of Hematology and Oncology, Naef K. Basile Cancer Institute, American University of Beirut Medical Center, Beirut, Lebanon.
  • Division of Hematology and Oncology, Lebanese American University Medical Center, Beirut, Lebanon.
  • Division of Hematology and Oncology, Saint Georges University Medical Center, Beirut, Lebanon.
  • Division of Hematology and Oncology, University Medical Center Hôtel-Dieu De France-Saint Joseph University of Beirut, Beirut, Lebanon.
  • Division of Hematology and Oncology, Hammoud Hospital University Medical Center, Beirut, Lebanon.

ORCID-Profile: Mohammad Hassan Hodroj, Hasan Numan, Firas Rammal, Ali Ghais, Maya Charafeddine, Cendrella Bou Orm, Samah Seif, Hady Ghanem, Malek Safa, Arafat Tfayli

Zitieren

APA

Hodroj, M. H., Numan, H., El-Halabi, L., Rammal, F., Ghais, A., Tfayli, R., Orm, A. B., Charafeddine, M., Orm, C. B., Haddad, K., Seif, S., Ghanem, H., El-Hachem, G., El Karak, F., Farhat, F., Safa, M., Khuri, F. R., & Tfayli, A. (2026). Impact of Lack of Access to Immunotherapy on Survival in Stage IV Non–Small Cell Lung Cancer: A Multicenter Retrospective Study From Lebanon. JCO Global Oncology, 12(7). https://doi.org/10.1200/go-26-00203

Vancouver

Hodroj MH, Numan H, El-Halabi L, Rammal F, Ghais A, Tfayli R, et al. Impact of Lack of Access to Immunotherapy on Survival in Stage IV Non–Small Cell Lung Cancer: A Multicenter Retrospective Study From Lebanon. JCO Global Oncology. 2026;12(7). doi:10.1200/go-26-00203

BibTeX
@article{Hodroj2026,
  author = {Hodroj, Mohammad Hassan and Numan, Hasan and El-Halabi, Laura and Rammal, Firas and Ghais, Ali and Tfayli, Rami and Orm, Abdallah Bou and Charafeddine, Maya and Orm, Cendrella Bou and Haddad, Karim and Seif, Samah and Ghanem, Hady and El-Hachem, Georges and El Karak, Fadi and Farhat, Fadi and Safa, Malek and Khuri, Fadlo R and Tfayli, Arafat},
  title = {Impact of Lack of Access to Immunotherapy on Survival in Stage IV Non–Small Cell Lung Cancer: A Multicenter Retrospective Study From Lebanon},
  journal = {JCO Global Oncology},
  year = {2026},
  volume = {12},
  number = {7},
  doi = {10.1200/go-26-00203}
}
Kostenlos starten →